CompaniesIkena Oncology

Ikena Oncology

defunct

About

Defunct Company

Areas of Focus

Categories

MergedBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (6)

Total Trials

6

As Lead Sponsor

6

As Collaborator

0

Total Enrollment

433

By Phase

PHASE1: 6

By Status

TERMINATED: 4WITHDRAWN: 1COMPLETED: 1

Clinical Trials Pipeline6 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2018

2019

2020

2021

2022

2023

2024

2025

2026

Today

Hover over trial bars to see details

Recent Trials

NCT06270082Lead Sponsor

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

PHASE1Terminated

75 participants

Started: Dec 18, 2023 · Completed: Sep 8, 2025

NCT05472506Lead Sponsor

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

PHASE1Withdrawn

Started: Mar 31, 2023 · Completed: Apr 30, 2023

NCT05228015Lead Sponsor

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

PHASE1Terminated

67 participants

Started: Jan 7, 2022 · Completed: Sep 9, 2024

NCT04682431Lead Sponsor

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

PHASE1Terminated

127 participants

Started: Nov 10, 2020 · Completed: Aug 31, 2023

NCT04691375Lead Sponsor

A Study of PY314 in Subjects With Advanced Solid Tumors

PHASE1Terminated

86 participants

Started: Oct 29, 2020 · Completed: Sep 22, 2023

View all 6 trials →

Funding History (20)

8-K

Oct 10, 2025

S-1

Sep 8, 2025

8-K/A

Aug 12, 2025

8-K

Aug 5, 2025

8-K

Aug 1, 2025

8-K

Jul 29, 2025

8-K

Jul 25, 2025

8-K

Jul 24, 2025

8-K

Jul 22, 2025

D

Jul 18, 2025

Related Companies

Inmagene

merged